Colorectal And Other GI Cancers

Blood Test Shows Promise for Early Colorectal Cancer Detection

January 17, 2018

Liquid biopsy that identifies circulating tumor cells in a blood sample has high accuracy for detecting colorectal cancer.

Do Pre-Op Cholesterol Levels Impact Post-Op Pain Outcomes?

December 13, 2017

The researchers observed a weak, but significant, positive correlation between total cholesterol and numeric rating scale scores on post operative days 0 and 1.

FDA Approves Second Biosimilar for the Treatment of Cancer

By December 01, 2017

Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer and the second biosimilar approved in the U.S. for the treatment of cancer.

FDA Approves InSure One to Aid in Detecting Lower GI Bleeding

By November 13, 2017

The InSure ONE requires a sample of water from the toilet bowl, after the stool surface has been brushed to release any blood.

PPI Use May Up Gastric Cancer Risk Even After <i>H. Pylori</i> Eradication Tx

November 02, 2017

Results showed that PPI use correlated with elevated risk of GC (hazard ratio, 2.44; 95% confidence interval, 1.42 to 4.2), while histamine-2 receptor antagonist use was not associated with increased risk (hazard ratio, 0.72; 95% confidence interval, 0.48 to 1.07).

Long-Term Aspirin Use Linked to Reduced Incidence of GI Cancers

By October 31, 2017

Researchers compared patients who were prescribed aspirin over a long period (for at least six months, average duration of aspirin prescribed was 7.7 years) with non-aspirin users and assessed the incidences of a number of cancers.

HCV Treatment With DAAs Reduces Liver Cancer Risk Significantly

By October 20, 2017

Study authors from the University of Washington, Seattle, and Veterans Affairs Puget Sound Healthcare System in Seattle sought to investigate whether HCV eradication with DAAs could lower the risk of liver cancer in patients.

Aspirin May Aid in Preventing Liver Cancer in Hep B Patients

October 20, 2017

The researchers found that the cumulative incidence of HCC in the treated group was significantly lower than that in the untreated group in five years.

Antibiotics May Reduce Infection Risk Post-Colorectal CA Surgery

October 19, 2017

The researchers found that patients who received oral antibiotics and MBP had a lower overall SSI rate than those who received MBP only (8 versus 27%; P=0.03).

Opdivo OK'd for Hepatocellular Carcinoma in Previously Treated Adults

By September 25, 2017

The overall response rate based on modified RECIST was 18.2% with complete response rate of 3.2% and partial response rate of 14.9%.

Keytruda Gains Additional Use in Advanced Gastric Cancers

By September 25, 2017

The overall response rate among patients was 13.3% (95% CI: 8.2, 20.0) with a complete response seen in 1.4% and partial response in 11.9%.

Histamine-Producing Probiotic Shows Promise in Treating Colorectal CA

September 20, 2017

The researchers found that administration of hdc+ Lactobacillus reuteri in the gut resulted in luminal hdc gene expression and production of histamine in the intestines of Hdc−/− mice.

FDA Approves Somatuline Depot to Treat Carcinoid Syndrome

By September 18, 2017

The 16-week study (n=115) enrolled patients with histopathologically-confirmed neuroendocrine tumors and a history of carcinoid syndrome who were treatment-naive or stable on another somatostatin analog.

First Biosimilar For Cancer Treatment Approved

By September 14, 2017

The approval was based on evidence from animal study data, human pharmacokinetic and pharmacodynamics data, and clinical immunogenicity data which demonstrated Mvasi is a biosimilar to Avastin.

Opdivo Approved to Treat MSI-H or dMMR Metastatic Colorectal Cancer

By August 01, 2017

In the Phase 2, multicenter, open-label, single-arm CheckMate -142 trial (n=74), qualified patients received Opdivo 3mg/kg intravenously (IV) every 2 weeks.

Two BLAs for Herceptin Biosimilars Submitted to FDA

By July 31, 2017

Two separate Biologics License Applications (BLAs) for biosimilar candidates to Herceptin (trastuzumab) have been submitted to the Food and Drug Administration (FDA).

Updated Prescribing Information for ChiRhoStim

By July 25, 2017

ChiRhoStim is available as 16mcg and 40mcg strength lyophilized powder in single-dose vials for reconstitution.

FDA Committee in Favor of Herceptin Biosimilar Approval

By July 14, 2017

Herceptin, a human epidermal growth factor receptor (HER2) inhibitor, is currently approved to treat HER2-overexpressing metastatic breast cancer as a single agent in patients who have received one or more chemotherapy regimens; or in combination with paclitaxel in patients who have not received chemotherapy.

Vectibix Approved as First-Line Tx for Wild-Type <i>RAS</i> mCRC

By June 30, 2017

In addition, the FDA has also approved a multigene, next-generation sequencing-based test to identify RAS mutation status of the patient's tumor and help physicians identify patients who will more likely benefit from Vectibix.

Task Force Issues New CRC Screening Recommendations

By June 21, 2017

Individuals with a family history of CRC in a first-degree relative diagnosed before age 60 should undergo colonoscopy every 5 years beginning at age 40 or 10 years before the age at which their relative was diagnosed.

NSAID Use May Benefit Certain Colorectal Cancer Survivors

June 20, 2017

The researchers administered detailed epidemiologic questionnaires to 2,419 patients age 18 to 74 years with incident invasive CRC, diagnosed from 1997 to 2008.

Gifts From Drug Manufacturers Influence Clinician's Rx Choices

June 07, 2017

Doctors were 78% more likely to prescribe a drug to treat metastatic renal cell carcinoma if they'd received a gift or small payment from that drug's manufacturer, compared to physicians who didn't receive any payments.

FDA to Review Opdivo for Hepatocellular Carcinoma Indication

By June 02, 2017

The sBLA submission was based on results from the Phase 1/2 CheckMate -040 study.

FDA Grants Unique Approval for Cancer Drug Keytruda

By May 24, 2017

Keytruda, a programmed death receptor-1 (PD-1)-blocking antibody, recently gained approval for urothelial carcinoma and metastatic non-small cell lung cancer (NSCLC).

Distinction Between Cancer Occurrence in U.S.-, African-Born Blacks

April 14, 2017

Research suggests differences in environmental, cultural, social, genetic factors

Opdivo Granted Priority Review for Colorectal Cancer Indication

By April 06, 2017

Opdivo, a human programmed death receptor-1 (PD-1)-blocking antibody, is already indicated for various renal and urologic cancers, head and neck cancer, lymphoma, skin cancer, and lung cancer.

Colorectal Risks ID'd With Consistent Antibiotic Use in Middle-Age

April 06, 2017

The researchers found that the use of antibiotics within the previous 4 years wasn't associated with a heightened risk of colorectal adenomas, but long-term use in the past was.

Researchers ID Possible Biomarker in Rectal CA Outcomes

April 04, 2017

The researchers observed a significant decrease of E-cadherin expression and a significant increased single-cell growth at the invasion front in tumor samples after radiochemotherapy versus primary biopsies of the tumor.

Are Antiemetic Prophylactics Being Overprescribed for Chemotherapy?

By March 24, 2017

Study authors identified a total of 8,545 patients undergoing 73,577 administrations of chemotherapy with minimal or low emetic risk.

Risks Following RFA for Liver Cancer in ESRD Patients on Hemodialysis Investigated

March 20, 2017

Dialyzed patients have higher in-hospital mortality, hemorrhagic complications after RFA for HCC